A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jiang, Yang, Yu, Zhou, Lin, Jiang, Ming, Hou, Mei
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876083/
https://www.ncbi.nlm.nih.gov/pubmed/20465813
http://dx.doi.org/10.1186/1471-2407-10-199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876083/
https://www.ncbi.nlm.nih.gov/pubmed/20465813
http://dx.doi.org/10.1186/1471-2407-10-199

Ejemplares similares